Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

NCT02920190 · Withdrawn

Last updated 2026-05-28

This clinical trial is testing whether a new approach targeting fat around the heart can help people who are overweight or obese and have a condition called monoclonal gammopathy.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Who can join Ages 18–70 · all sexes

Timeline Started 2020-09 · est. completion 2021-12

What this study is testing ClinicalTrials.gov NCT02920190 ↗

Description as written by the study sponsor.

The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.

Treatments tested

Liraglutide also known as Victoza Drug

1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months

Main thing measured	Change in Epicardial Fat Thickness
Sponsor	University of Miami
Conditions studied	Monoclonal Gammopathies, Overweight, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02920190 ↗